Literature DB >> 33215357

Human Induced Pluripotent Stem Cells as a Disease Model System for Heart Failure.

Anton Deicher1, Timon Seeger2,3.   

Abstract

PURPOSE OF REVIEW: Heart failure is among the most prevalent disease complexes overall and is associated with high morbidity and mortality. The underlying aetiology is manifold including coronary artery disease, genetic alterations and mutations, viral infections, adverse immune responses, and cardiac toxicity. To date, no specific therapies have been developed despite notable efforts. This can especially be attributed to hurdles in translational research, mainly due to the lack of proficient models of heart failure limited translation of therapeutic approaches from bench to bedside. RECENT
FINDINGS: Human induced pluripotent stem cells (hiPSCs) are rising in popularity, granting the ability to divide infinitely, to hold human, patient-specific genome, and to differentiate into any human cell, including cardiomyocytes (hiPSC-CMs). This brings magnificent promise to cardiological research, providing the possibility to recapitulate cardiac diseases in a dish. Advances in yield, maturity, and in vivo resemblance due to straightforward, low-cost protocols, high-throughput approaches, and complex 3D cultures have made this tool widely applicable. In recent years, hiPSC-CMs have been used to model a wide variety of cardiac diseases, bringing along the possibility to not only elucidate molecular mechanisms but also to test novel therapeutic approaches in the dish. Within the last decade, hiPSC-CMs have been exponentially employed to model heart failure. Constant advancements are aiming at improvements of differentiation protocols, hiPSC-CM maturity, and assays to elucidate molecular mechanisms and cellular functions. However, hiPSC-CMs are remaining relatively immature, and in vitro models can only partially recapitulate the complex interactions in vivo. Nevertheless, hiPSC-CMs have evolved as an essential model system in cardiovascular research.

Entities:  

Keywords:  Cardiomyocytes; Disease model; Heart failure; Human induced pluripotent stem cells

Year:  2020        PMID: 33215357      PMCID: PMC7817647          DOI: 10.1007/s11897-020-00497-5

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  89 in total

1.  Polyploidy in Cardiomyocytes: Roadblock to Heart Regeneration?

Authors:  Wouter Derks; Olaf Bergmann
Journal:  Circ Res       Date:  2020-02-13       Impact factor: 17.367

2.  A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.

Authors:  Timon Seeger; Rajani Shrestha; Chi Keung Lam; Caressa Chen; Wesley L McKeithan; Edward Lau; Alexa Wnorowski; George McMullen; Matthew Greenhaw; Jaecheol Lee; Angelos Oikonomopoulos; Soah Lee; Huaxiao Yang; Mark Mercola; Matthew Wheeler; Euan A Ashley; Fan Yang; Ioannis Karakikes; Joseph C Wu
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

Review 3.  Human Cardiac Organoids for Disease Modeling.

Authors:  Bramasta Nugraha; Michele F Buono; Lisa von Boehmer; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  Clin Pharmacol Ther       Date:  2018-12-21       Impact factor: 6.875

4.  Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation.

Authors:  Maike Marczenke; Jakob Fell; Ilaria Piccini; Albrecht Röpke; Guiscard Seebohm; Boris Greber
Journal:  Stem Cell Res       Date:  2017-03-23       Impact factor: 2.020

Review 5.  Fluorescent, Bioluminescent, and Optogenetic Approaches to Study Excitable Physiology in the Single Cardiomyocyte.

Authors:  Connor N Broyles; Paul Robinson; Matthew J Daniels
Journal:  Cells       Date:  2018-05-31       Impact factor: 6.600

Review 6.  Endothelial cell-cardiomyocyte crosstalk in heart development and disease.

Authors:  Andrea Colliva; Luca Braga; Mauro Giacca; Serena Zacchigna
Journal:  J Physiol       Date:  2019-03-27       Impact factor: 5.182

7.  miR-30e-5p Mitigates Hypoxia-Induced Apoptosis in Human Stem Cell-Derived Cardiomyocytes by Suppressing Bim.

Authors:  Binhai Mo; Xiaodan Wu; Xiantao Wang; Jian Xie; Ziliang Ye; Lang Li
Journal:  Int J Biol Sci       Date:  2019-04-21       Impact factor: 6.580

8.  An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes.

Authors:  Wesley L McKeithan; Alex Savchenko; Michael S Yu; Fabio Cerignoli; Arne A N Bruyneel; Jeffery H Price; Alexandre R Colas; Evan W Miller; John R Cashman; Mark Mercola
Journal:  Front Physiol       Date:  2017-10-11       Impact factor: 4.566

Review 9.  Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Pranav Machiraju; Steven C Greenway
Journal:  World J Stem Cells       Date:  2019-01-26       Impact factor: 5.326

10.  Barth Syndrome: Exploring Cardiac Metabolism with Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Erica M Fatica; Gina A DeLeonibus; Alisha House; Jillian V Kodger; Ryan W Pearce; Rohan R Shah; Liraz Levi; Yana Sandlers
Journal:  Metabolites       Date:  2019-12-17
View more
  2 in total

Review 1.  Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases.

Authors:  Haocheng Lu; Jifeng Zhang; Y Eugene Chen; Minerva T Garcia-Barrio
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-15       Impact factor: 3.947

2.  miR-199a Overexpression Enhances the Potency of Human Induced-Pluripotent Stem-Cell-Derived Cardiomyocytes for Myocardial Repair.

Authors:  Weihua Bian; Wangping Chen; Thanh Nguyen; Yang Zhou; Jianyi Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.